FDA updates watch list

02/13/2013 | Medscape (free registration)

The FDA added GlaxoSmithKline's leukemia drug Arzerra, or ofatumumab; UCB's epilepsy, liver and kidney drug Vimpat, or lacosamide; and Acorda Therapeutics' multiple sclerosis, kidney and liver drug Ampyra, or dalfampridine, to its list of products to monitor due to new safety information or possible signals of serious risks. The FDA received reports of potential adverse events involving the treatments in last year's third quarter.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL